Mary Jenkins - Sarepta Therapeutics Sr Relations

S1RP34 Stock  BRL 31.35  0.72  2.35%   

Insider

Mary Jenkins is Sr Relations of Sarepta Therapeutics
Phone617 274 4000
Webhttps://www.sarepta.com

Sarepta Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.1149) % which means that it has lost $0.1149 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.591) %, meaning that it generated substantial loss on money invested by shareholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Sarepta Therapeutics has accumulated 1.1 B in total debt with debt to equity ratio (D/E) of 2.19, implying the company greatly relies on financing operations through barrowing. Sarepta Therapeutics has a current ratio of 6.11, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sarepta Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Sarepta Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sarepta Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sarepta to invest in growth at high rates of return. When we think about Sarepta Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Vamsi PudipeddiAlign Technology
51
Jan SiegmundCognizant Technology Solutions
59
Daniel CamargoMAHLE Metal Leve
N/A
Lawrence WieserCognizant Technology Solutions
N/A
JanFrederek ThieleMAHLE Metal Leve
N/A
John KimCognizant Technology Solutions
55
Isabel JanciThe Home Depot
N/A
Simon BeardAlign Technology
56
Julie ColettiAlign Technology
54
Nathan QuyeMAHLE Metal Leve
N/A
Richard McPhailThe Home Depot
52
Zelko RelicAlign Technology
58
Andre VelosoBemobi Mobile Tech
N/A
Shirley StacyAlign Technology
N/A
Rashmi VasishtCognizant Technology Solutions
N/A
Emory WrightAlign Technology
53
Jrg StratmannMAHLE Metal Leve
54
Stuart HockridgeAlign Technology
51
Philipp KuckuckMAHLE Metal Leve
N/A
Sara GormanThe Home Depot
N/A
Anil CheriyanCognizant Technology Solutions
65
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. SAREPTA THERDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 866 people. Sarepta Therapeutics (S1RP34) is traded on Sao Paulo Exchange in Brazil and employs 840 people.

Management Performance

Sarepta Therapeutics Leadership Team

Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Ciambrone, Ex Operations
Dallan Murray, VP Officer
Ian Estepan, Ex CFO
Douglas Esq, CEO Pres
Alison Nasisi, Chief VP
Bilal Arif, VP Operations
Diane Berry, Sr Affairs
Ryan Brown, Gen VP
Louise RodinoKlapac, Chief VP
Mary Jenkins, Sr Relations

Sarepta Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sarepta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Sarepta Stock

When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Sarepta Stock refer to our How to Trade Sarepta Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.